Clinical trial NCT05352815: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Official title: A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2022-04-29
Enrollment: 1291
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.

The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.

Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.

Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.

The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.

Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.


Eligibility criteria: Key inclusion criteria

1. Male or female and age above or equal to 18 years at the time of signing informed consent.
2. Diagnosed with type 2 diabetes mellitus 180 days or more before screening.
3. HbA1c of 7.0 10.0% (53.0 85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
4. Treated with once daily or twice daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20- 80 units/day for 90 days or more before screening. Short term bolus insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes. The treatment can be with or without any of the following anti diabetic drugs with stable doses for 90 days or more before screening:

   * Metformin
   * Sulfonylureas (a)
   * Meglitinides (glinides) (a)
   * DPP 4 inhibitors (a)
   * Sodium glucose co transporter 2 inhibitors
   * Alpha glucosidase inhibitors
   * Thiazolidinediones
   * Marketed oral combination products only including the products listed above.
5. Body mass index (BMI) below or equal to 40.0 kg/m\^2. (a) Sulfonylureas, meglitinides (glinides) and DPP 4 inhibitors must be discontinued at randomisation.

Key exclusion criteria

1. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
2. Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
3. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening.
4. Any episodes (as declared by the participant or in the medical records.) of diabetic ketoacidosis within 90 days before screening.
5. Presence or history of pancreatitis (acute or chronic) within 180 days before screening.
6. Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening.
7. Chronic heart failure classified as being in New York Heart Association Class IV at screening.
8. Recurrent severe hypoglycaemic episodes within the last year (12 months) as judged by the investigator.
9. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Primary outcomes:
measure: Change in Glycated Haemoglobin (HbA1c)
timeFrame: Baseline (Week 0), Week 52
Secondary outcomes:
measure: Change in Body Weight
timeFrame: Baseline (Week 0), Week 52
measure: Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3)
timeFrame: From baseline week 0 to week 57
measure: Percentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6
timeFrame: From week 48 to week 52
measure: Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6
timeFrame: From week 48 to week 52
measure: Percentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6
timeFrame: From week 48 to week 52
measure: Change in Fasting Plasma Glucose (FPG)
timeFrame: Baseline (Week 0), Week 52
measure: Weekly Basal Insulin Dose
timeFrame: From week 50 to week 52
measure: Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)
timeFrame: From baseline week 0 to week 57
measure: Number of Severe Hypoglycaemic Episodes (Level 3)
timeFrame: From baseline week 0 to week 57
Other outcomes:
Locations:
city: Gilbert
country: United States
facility: Pri Med Grp dba/Gil Ctr Fam
state: Arizona
city: Little Rock
country: United States
facility: Medical Investigations, Inc.
state: Arkansas
city: Concord
country: United States
facility: John Muir Physicians Network
state: California
city: Escondido
country: United States
facility: Headlands Research California, LLC
state: California
city: La Jolla
country: United States
facility: Scripps Whittier Diabetes Inst
state: California
city: Lomita
country: United States
facility: Torrance Clin Res Inst, Inc.
state: California
city: Los Alamitos
country: United States
facility: Pacific Clinical Studies
state: California
city: Los Angeles
country: United States
facility: Downtown LA Res Ctr. Inc.
state: California
city: Los Angeles
country: United States
facility: Velocity Clin Res Wstlke
state: California
city: Northridge
country: United States
facility: Valley Clinical Trials, Inc.
state: California
city: San Ramon
country: United States
facility: NorCal Endocrinology and Internal Medicine
state: California
city: Walnut Creek
country: United States
facility: Diablo Clinical Research, Inc.
state: California
city: Denver
country: United States
facility: Creekside Endocrine Associates, PC
state: Colorado
city: Clearwater
country: United States
facility: Clinical Res Of W Florida Inc
state: Florida
city: Fleming Island
country: United States
facility: Northeast Research Institute
state: Florida
city: New Port Richey
country: United States
facility: Suncoast Clin Res Port Richey
state: Florida
city: West Palm Beach
country: United States
facility: Metabolic Research Institute Inc
state: Florida
city: Albany
country: United States
facility: Javara/Privia Med Grp GA,LLC
state: Georgia
city: Fayetteville
country: United States
facility: Javara Inc.
state: Georgia
city: Lawrenceville
country: United States
facility: Physicians Research Assoc. LLC
state: Georgia
city: Skokie
country: United States
facility: Endeavor Health
state: Illinois
city: West Des Moines
country: United States
facility: Iowa Diab & Endo Res Center
state: Iowa
city: Topeka
country: United States
facility: Cotton O'Neil Clin Research Ctr
state: Kansas
city: Lexington
country: United States
facility: The Research Group of Lexington LLC
state: Kentucky
city: New Orleans
country: United States
facility: New Orleans Center for Clinical Research
state: Louisiana
city: Slidell
country: United States
facility: Ileana J Tandron APMC
state: Louisiana
city: Hyattsville
country: United States
facility: MedStar Hlth Res Institute
state: Maryland
city: Boston
country: United States
facility: Brigham & Women's Hospital
state: Massachusetts
city: Buckley
country: United States
facility: Northern Pines Hlth Ctr, PC
state: Michigan
city: Flint
country: United States
facility: Elite Research Center
state: Michigan
city: Minneapolis
country: United States
facility: International Diabetes Center
state: Minnesota
city: Jefferson City
country: United States
facility: Jefferson City Medical Group, PC
state: Missouri
city: Omaha
country: United States
facility: Methodist Phys. Clinic
state: Nebraska
city: Omaha
country: United States
facility: University of NE Med Ctr
state: Nebraska
city: Las Vegas
country: United States
facility: Palm Research Center Inc.
state: Nevada
city: Nashua
country: United States
facility: Southern New Hampshire Diabete
state: New Hampshire
city: Albuquerque
country: United States
facility: Albuquerque Clin Trials, Inc.
state: New Mexico
city: New Windsor
country: United States
facility: Mid Hudson Medical Research, PLLC
state: New York
city: West Seneca
country: United States
facility: Southgate Medical Group, LLP
state: New York
city: Greensboro
country: United States
facility: PharmQuest Life Sciences LLC
state: North Carolina
city: Columbus
country: United States
facility: Central Ohio Clinical Research LLC
state: Ohio
city: Wadsworth
country: United States
facility: New Venture Medical Research
state: Ohio
city: Bartlett
country: United States
facility: AM Diabetes And Endocrinology Center
state: Tennessee
city: Bristol
country: United States
facility: Holston Medical Group_Bristol
state: Tennessee
city: Morristown
country: United States
facility: HealthStar Physicians PC
state: Tennessee
city: Amarillo
country: United States
facility: Amarillo Med Spec LLP
state: Texas
city: Austin
country: United States
facility: Texas Diabetes & Endocrinology, P.A._Austin
state: Texas
city: Austin
country: United States
facility: Texas Diabetes & Endocrinology, P.A._Austin
state: Texas
city: Dallas
country: United States
facility: Velocity Clinical Res-Dallas
state: Texas
city: Dallas
country: United States
facility: Univ of TX SW Med Ctr Dallas
state: Texas
city: Houston
country: United States
facility: PrimeCare Medical Group
state: Texas
city: Houston
country: United States
facility: Javara Inc. / Privia Medical Group Gulf Coast PLLC
state: Texas
city: Houston
country: United States
facility: PlanIt Research, PLLC
state: Texas
city: Hurst
country: United States
facility: Protenium Clinical Research
state: Texas
city: Laredo
country: United States
facility: Andres Garcia-Zuniga, MD, P.A
state: Texas
city: Laredo
country: United States
facility: Milton Haber, M.D.
state: Texas
city: Longview
country: United States
facility: DCOL Ctr for Clin Res
state: Texas
city: Round Rock
country: United States
facility: Texas Diabetes &Endocrinology
state: Texas
city: San Antonio
country: United States
facility: Sun Research Institute
state: Texas
city: San Antonio
country: United States
facility: Briggs Clinical Research, LLC
state: Texas
city: San Marcos
country: United States
facility: Javara Inc Privia Grp Gulf Cst
state: Texas
city: Sugar Land
country: United States
facility: SimCare, PLLC
state: Texas
city: Forest
country: United States
facility: Javara Inc/Privia Md GpLLC Fst
state: Virginia
city: Norfolk
country: United States
facility: Eastern Virginia Medical School
state: Virginia
city: Winchester
country: United States
facility: Amherst Family Practice P.C.
state: Virginia
city: Darlinghurst
country: Australia
facility: Holdsworth House Clinical Research
state: New South Wales
city: Darlinghurst
country: Australia
facility: Momentum Clinical Research Darlinghurst
state: New South Wales
city: Kotara
country: Australia
facility: Novatrials
state: New South Wales
city: Wollongong
country: Australia
facility: Illawarra Diabetes Service Clinical Trials & Research Unit
state: New South Wales
city: Herston
country: Australia
facility: Royal Brisbane and Women's Hospital
state: Queensland
city: Oaklands Park
country: Australia
facility: Southern Adelaide Diabetes & Endocrine Services
state: South Australia
city: Launceston
country: Australia
facility: Launceston General Hospital
state: Tasmania
city: Geelong
country: Australia
facility: Barwon Health (The Geelong Hospital)
state: Victoria
city: Melbourne
country: Australia
facility: The Alfred Hospital
state: Victoria
city: Bonheiden
country: Belgium
facility: Imeldaziekenhuis - Bonheiden - Department of Endocrinology
city: Brussel
country: Belgium
facility: UZ Brussel - Universitair Ziekenhuis Brussel
city: Bruxelles
country: Belgium
facility: Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
city: Edegem
country: Belgium
facility: UZA - UZ Antwerpen - Department of Endocrinology
city: Kortrijk
country: Belgium
facility: AZ Groeninge - Kortrijk - Centrum Endo - Diabetologie
city: Leuven
country: Belgium
facility: UZ Leuven - Endocrinology
city: Burgas
country: Bulgaria
facility: "IPSMC - d-r Nikolay Kostadinov" EOOD
city: Kyustendil
country: Bulgaria
facility: 'Medical center Medi city 21' OOD
city: Pleven
country: Bulgaria
facility: DCC I- Pleven EOOD
city: Plovdiv
country: Bulgaria
facility: UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
city: Sofia
country: Bulgaria
facility: MMA-MHAT Sofia, Clinic of Endocrinology and Metab. Diseases
city: Hefei
country: China
facility: Anhui Provincial Hospital-Endocrinology
state: Anhui
city: Beijing
country: China
facility: Peking University People's Hospital-Endocrinology
state: Beijing
city: ChongQing
country: China
facility: Chongqing University Three Gorges Hospital
state: Chongqing
city: Huizhou
country: China
facility: Huizhou Central People's Hospital-Endocrinology
state: Guangdong
city: Hengshui
country: China
facility: Harrison International Peace Hospital-Endocrinology
state: Hebei
city: Hengshui
country: China
facility: Harrison International Peace Hospital
state: Hebei
city: Kaifeng
country: China
facility: Huaihe Hospital of Henan University-Endocrinology
state: Henan
city: Changzhou
country: China
facility: Changzhou No.2 People's Hospital, Yanghu Branch
state: Jiangsu
city: Changzhou
country: China
facility: The First People's Hospital of Changzhou
state: Jiangsu
city: Nanjing
country: China
facility: The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
state: Jiangsu
city: Nanjing
country: China
facility: The Second Affiliated Hospital of Nanjing Medical University_Nanjing
state: Jiangsu
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Soochow University-Endocrinology
state: Jiangsu
city: Zhenjiang
country: China
facility: The Affiliated Hospital of Jiangsu University-Endocrinology
state: Jiangsu
city: Ji'nan
country: China
facility: Jinan Central Hospital
state: Shandong
city: Shanghai
country: China
facility: Shanghai Fifth People's Hospital-Endocrinology
state: Shanghai
city: Tianjin
country: China
facility: General Hospital of Tianjin Medical University-Endocrinology
state: Tianjin
city: Tianjin
country: China
facility: The Second Hospital of Tianjin Medical University
state: Tianjin
city: Zagreb
country: Croatia
facility: Poliklinika Solmed
state: Grad Zagreb
city: Osijek
country: Croatia
facility: Poliklinika SLAVONIJA OSIJEK
state: Osječko - Baranjska Županija
city: Osijek
country: Croatia
facility: Klinicki bolnicki centar Osijek
city: Pula
country: Croatia
facility: Opca bolnica Pula
city: Rijeka
country: Croatia
facility: KBC Rijeka, Endokrinologija
city: Kuopio
country: Finland
facility: Health Step Finland Oy
city: Raisio
country: Finland
facility: Raision sosiaali- ja terveyskeskus
city: Tampere
country: Finland
facility: Tampereen diabetesvastaanotto
city: Turku
country: Finland
facility: Turku University Hospital
city: Ähtäri
country: Finland
facility: Ähtärin terveysasema
city: Ahmedabad
country: India
facility: Gujarat Endocrine Centre
state: Gujarat
city: Kozhikode
country: India
facility: Government Medical College, Kozhikode
state: Kerala
city: Thriruvananthapuram
country: India
facility: Jothydev's Diabetes & Research Center
state: Kerala
city: Indore
country: India
facility: TOTALL Diabetes Hormone Institute
state: Madhya Pradesh
city: Kolhapur
country: India
facility: Excel Endocrine Centre
state: Maharashtra
city: Mumbai
country: India
facility: Seth GS medical college and KEM Hospital
state: Maharashtra
city: Chandigarh
country: India
facility: Post Graduate Institute of Medical Education & Research
state: Punjab
city: Chennai
country: India
facility: M.V.Hospital for Diabetes Pvt. Ltd.
state: Tamil Nadu
city: Madurai
country: India
facility: Arthur Asirvatham hospital,
state: Tamil Nadu
city: Hyderabad
country: India
facility: Osmania General Hospital
state: Telangana
city: Hyderabad
country: India
facility: Ramdev Rao Hospital
state: Telangana
city: New Delhi
country: India
facility: Lady Hardinge Medical College
city: Bari
country: Italy
facility: A.O.U. Consorziale Policlinico di Bari
state: BA
city: Catanzaro
country: Italy
facility: Policlinico Mater Domini Università di Catanzaro
city: Chiavari (genova)
country: Italy
facility: ASL 4 Chiavarese
city: Milano
country: Italy
facility: ASST Grande Ospedale Metropolitano Niguarda
city: Koriyama-shi
country: Japan
facility: Seino Internal Medicine Clinic
state: Fukushima, Japan
city: Sapporo-shi, Hokkaido
country: Japan
facility: Manda Memorial Hospital
state: Hokkaido, Japan
city: Chigasaki-shi, Kanagawa
country: Japan
facility: Hayashi Diabetes Clinic
state: Kanagawa, Japan
city: Chigasaki-shi
country: Japan
facility: Hayashi Diabetes Clinic
state: Kanagawa, Japan
city: Kumamoto-shi
country: Japan
facility: Jinnouchi Hospital
state: Kumamoto, Japan
city: Miyazaki-shi
country: Japan
facility: Heiwadai Hospital
state: Miyazaki
city: Arakawa-ku, Tokyo
country: Japan
facility: Kumanomae Nishimura Internal Medical Clinic
city: Chiba-shi, Chiba
country: Japan
facility: Akaicho Clinic
city: Fukuoka-shi, Fukuoka
country: Japan
facility: Futata Tetsuhiro Clinic Meinohama
city: Fukuoka-shi, Fukuoka
country: Japan
facility: Kunisaki Makoto Clinic
city: Hokkaido
country: Japan
facility: Sasaki Internal Medicine
city: Kumamoto
country: Japan
facility: Yoshimura clinic
city: Saga-shi, Saga
country: Japan
facility: Hisatomi Clinic
city: Tokyo
country: Japan
facility: Tokyo-Eki Center-building Clinic
city: Tokyo
country: Japan
facility: Fukuwa Clinic
city: Yokohama-shi, Kanagawa
country: Japan
facility: Yokohama City University Hospital, Endocrinology, Metabolism
city: Cheonan
country: Korea, Republic of
facility: Soonchunhyang University Hospital
state: Chungcheongnam-do
city: Ansan
country: Korea, Republic of
facility: Korea University Ansan Hospital
state: Gyeonggi-do
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital_Seongnam-si
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul Saint Mary's Hospital
city: Seoul
country: Korea, Republic of
facility: Nowon Eulji Medical Center, Eulji University
city: Wonju
country: Korea, Republic of
facility: Wonju Severance Christian Hospital
city: Monterrey
country: Mexico
facility: Hospital Universitario Dr. José Eleuterio González_Monterrey
state: Nuevo León
city: Aguascalientes
country: Mexico
facility: Centro de Investigación Cardiometabólica de Aguascalientes
city: Mexico City
country: Mexico
facility: Clínicos Asociados BOCM, S.C.
city: Bodø
country: Norway
facility: Nordlandssykehuset Bodø
city: Drammen
country: Norway
facility: Drammen sykehus - Vestre Viken HF
city: Hamar
country: Norway
facility: Sykehuset Innlandet HF Hamar
city: Oslo
country: Norway
facility: Oslo universitetssykehus Aker
city: Trondheim
country: Norway
facility: St. Olavs Hospital HF
city: Lublin
country: Poland
facility: NZOZ Przychodnia Specjalistyczna Medica
state: Lubelski
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne (UCK)
city: Lublin
country: Poland
facility: NZOZ "CenterMed Lublin" Sp. z o.o.
city: Warszawa
country: Poland
facility: Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
city: Senhora Da Hora, Matosinhos
country: Portugal
facility: Unidade Local De Saude De Matosinhos E.P.E.
state: Matosinhos
city: Almada
country: Portugal
facility: Unidade Local De Saude De Almada-Seixal E.P.E.
city: Aveiro
country: Portugal
facility: Unidade Local De Saude Da Regiao De Aveiro E.P.E.
city: Braga
country: Portugal
facility: Hospital de Braga
city: Lisboa
country: Portugal
facility: Centro Hospitalar Lisboa Ocidental
city: Lisboa
country: Portugal
facility: Hospital Da Luz S.A.
city: Matosinhos
country: Portugal
facility: Unidade Local de Saúde de Matosinhos
city: Vila Nova de Gaia
country: Portugal
facility: Hospital Luz Arrabida, S.A.
city: Bayamon
country: Puerto Rico
facility: Advanced Clinical Research LLC
city: Manati
country: Puerto Rico
facility: Manati Ctr For Clin Research
city: Bucharest
country: Romania
facility: Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
state: Bucurestii
city: Baia Mare
country: Romania
facility: CMI Diabet, Nutritie, Boli Metabolice "Dr Pop Lavinia"
state: Maramures
city: Brasov
country: Romania
facility: Mariodiab Clinic SRL
city: Iasi
country: Romania
facility: SC Consultmed SRL
city: Satu-Mare
country: Romania
facility: Clinica Korall S.R.L. Satu Mare
city: Suceava
country: Romania
facility: Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava
city: Tumen
country: Russian Federation
facility: Tumen State Medical University
state: Russia
city: Arkhangelsk
country: Russian Federation
facility: Arkhangelsk Regional Clinical Hospital
city: Ekaterinburg
country: Russian Federation
facility: Sverdlovsk Regional Clinical Hospital #1
city: Irkutsk
country: Russian Federation
facility: Irkutsk State Medical Academy of Postgraduate Education
city: Kursk
country: Russian Federation
facility: Limited Liability Company "AriVa-Med"
city: Saint-Petersburg
country: Russian Federation
facility: City Consultative & Diagnostic Centre #1
city: Saratov
country: Russian Federation
facility: Saratov regional clinical hospital
city: Belgrade
country: Serbia
facility: Endocrinology, Diabetes and Metabolism Diseases Clinic
city: Johannesburg
country: South Africa
facility: Deepak Lakha
state: Gauteng
city: Johannesburg
country: South Africa
facility: Hemant Makan
state: Gauteng
city: Johannesburg
country: South Africa
facility: Wits Bara Clinical Trial Site
state: Gauteng
city: Durban
country: South Africa
facility: Dr Pillay's Rooms
state: KwaZulu-Natal
city: Brits
country: South Africa
facility: Armansis Medical Centre
state: North West
city: Cape Town
country: South Africa
facility: Langeberg Clinical Trials
state: Western Cape
city: Alberton
country: South Africa
facility: Netcare Alberton Hospital
city: Changhua City
country: Taiwan
facility: Changhua Christian Hospital
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Tainan City
country: Taiwan
facility: National Cheng Kung University Hospital
city: Tainan City
country: Taiwan
facility: Chi Mei Medical Center
city: Taipei city
country: Taiwan
facility: Taipei Medical University Hospital
city: Ankara
country: Turkey
facility: Ankara Universitesi Ibni Sina Hastanesi
state: Altindag
city: Adana
country: Turkey
facility: Cukurova Universitesi Tip Fakultesi
city: Ankara
country: Turkey
facility: Gulhane Egitim Arastirma Hastanesi
city: Istanbul
country: Turkey
facility: Haseki Sultangazi
city: Istanbul
country: Turkey
facility: T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
city: Istanbul
country: Turkey
facility: T.C. S.B. Ist Il SagMud Pendik Egitim ve Arastirma Hastanesi
city: Tekirdag
country: Turkey
facility: Tekirdag Namık Kemal UTF
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: